Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...
CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a significant ...
Patients with CTD-ILD and a parenchymal PH phenotype experience significantly worse clinical outcomes than those with a vascular PH phenotype.
InvestorsHub on MSN
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses
Exagen delivered record first-quarter revenue and improved adjusted EBITDA metrics as the autoimmune diagnostics company ...
What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...
CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus ...
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care CARLSBAD, Calif., Dec. 12, ...
What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results